Noninferiority on Overall Survival of Every-2-Weeks vs Weekly Schedule of Cetuximab for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer

被引：0

作者：

Kasper-Virchow, Stefan ^{[1
]}

Cheng, Ann-Lll ^{[2
]}

Overkamp, Friedrich ^{[3
]}

Rouyer, Magali ^{[4
]}

Foch, Caroline ^{[5
]}

Lamy, Francois-Xavier ^{[5
]}

Esser, Regina ^{[5
]}

Messinger, Diethelm ^{[6
]}

Rothe, Vivien ^{[6
]}

Chen, Wenfeng ^{[7
]}

Brodowicz, Thomas ^{[8
]}

Zielinski, Christoph ^{[9
,10
]}

机构：

[1] Univ Hosp Essen, West German Canc Ctr, Essen, Germany

[2] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[3] Oncologianova GmbH, Recklinghausen, Germany

[4] Univ Bordeaux, INSERM, CIC 1401, Bordeaux Pharmacoepi BPE, Bordeaux, France

[5] Merck KGaA, Darmstadt, Germany

[6] Prometris GmbH, Mannheim, Germany

[7] Merck Serono, Shanghai, Peoples R China

[8] Med Univ Vienna, Dept Med Oncol, Gen Hosp, Internal Med, Vienna, Austria

[9] Vienna Gen Hosp, Vienna, Austria

[10] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1019

引用

页码：219 / 220

页数：2

共 50 条

[41] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial [J].

Kasper, Stefan ;

Meiler, Johannes ;

Knipp, Heike ;

Hohler, Thomas ;

Reimer, Peter ;

Steinmetz, Tilman ;

Berger, Winfried ;

Linden, Gabriele ;

Reis, Henning ;

Markus, Peter ;

Paul, Andreas ;

Dechene, Alexander ;

Schumacher, Brigitte ;

Kostbade, Karina ;

Virchow, Isabel ;

Ting, Saskia ;

Worm, Karl ;

Schmid, Kurt W. ;

Herold, Thomas ;

Wiesweg, Marcel ;

Schuler, Martin ;

Trarbach, Tanja .

CLINICAL COLORECTAL CANCER, 2020, 19 (04) :236-+

[42] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study [J].

Yamaguchi, K. ;

Ando, M. ;

Ooki, A. ;

Beier, F. ;

Guenther, S. ;

Von Hohnhorst, P. ;

Van Cutsem, E. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S370-S371

[43] Therapeutic effect of biweekly cetuximab combined with first-line chemotherapy on KRAS/RAS wild-type advanced colorectal cancer [J].

Li, Jing ;

Li, Jianjiong .

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (10) :12348-12355

[44] Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer [J].

Patel, Shiven B. ;

Gill, David ;

Garrido-Laguna, Ignacio .

ONCOTARGETS AND THERAPY, 2016, 9 :75-86

[45] FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study [J].

Brodowicz, T. ;

Ciuleanu, T. E. ;

Radosavljevic, D. ;

Shacham-Shmueli, E. ;

Vrbanec, D. ;

Plate, S. ;

Mrsic-Krmpotic, Z. ;

Dank, M. ;

Purkalne, G. ;

Messinger, D. ;

Zielinski, C. C. .

ANNALS OF ONCOLOGY, 2013, 24 (07) :1769-1777

[46] Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer [J].

Mrabti, Hind ;

De la Fouchardiere, Christelle ;

Desseigne, Francoise ;

Dussart, Sophie ;

Negrier, Sylvie ;

Errihani, Hassan .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2009, 5 (04) :272-276

[47] Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer A Randomized Clinical Trial [J].

Watanabe, Jun ;

Muro, Kei ;

Shitara, Kohei ;

Yamazaki, Kentaro ;

Shiozawa, Manabu ;

Ohori, Hisatsugu ;

Takashima, Atsuo ;

Yokota, Mitsuru ;

Makiyama, Akitaka ;

Akazawa, Naoya ;

Ojima, Hitoshi ;

Yuasa, Yasuhiro ;

Miwa, Keisuke ;

Yasui, Hirofumi ;

Oki, Eiji ;

Sato, Takeo ;

Naitoh, Takeshi ;

Komatsu, Yoshito ;

Kato, Takeshi ;

Hihara, Masamitsu ;

Soeda, Junpei ;

Misumi, Toshihiro ;

Yamamoto, Kouji ;

Akagi, Kiwamu ;

Ochiai, Atsushi ;

Uetake, Hiroyuki ;

Tsuchihara, Katsuya ;

Yoshino, Takayuki .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (15) :1271-1282

[48] Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer [J].

Laurent-Puig, Pierre ;

Grisoni, Marie-Lise ;

Heinemann, Volker ;

Liebaert, Francois ;

Neureiter, Daniel ;

Jung, Andreas ;

Montestruc, Francois ;

Gaston-Mathe, Yann ;

Thiebaut, Raphaeele ;

Stintzing, Sebastian .

CLINICAL CANCER RESEARCH, 2019, 25 (01) :134-141

[49] Role of cetuximab in first-line treatment of metastatic colorectal cancer [J].

Miguel Jhonatan Sotelo ;

Beatriz García-Paredes ;

Carlos Aguado ;

Javier Sastre ;

Eduardo Díaz-Rubio .

World Journal of Gastroenterology, 2014, (15) :4208-4219

[50] Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study [J].

Xu, Chang ;

Ren, Jing ;

Liu, Changqing ;

Gai, Yi ;

Cheng, Xiangyu ;

Wang, Yusheng ;

Wang, Guangyu .

ANTI-CANCER DRUGS, 2025, 36 (05) :383-393

← 1 2 3 4 5 →